Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacterial Composition and Immune Responses During Influenza Infection
NCT02597647Phase 1Completed
- Sponsor
- University of California, Los Angeles
- Start
- Feb 2011
- Primary completion
- Apr 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal) in influenza (2 arms), sponsored by University of California, Los Angeles. Primary endpoints: Changes in the bacterial composition (Bacterial 'microbiome') over time and Changes in gene expression in the nasal lining of study participants. Started Feb 2011; status: completed.
02
Drugs
influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02597647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597647.